FDA Issues 483 to Novo Nordisk for Inadequate Sterility Controls

The FDA slammed Denmark’s Novo Nordisk for numerous GMP issues in a 13-item Form 483 for inadequate controls for sterility, environmental monitoring, labeling and written procedures.
Source: Drug GMP Report